Manufacturing and testing of an allogeneic gamma delta T cell therapy for the treatment of cancer

Projektinformationen

OmnImmune

ID Finanzhilfevereinbarung: 783506

DOI 10.3030/783506

Abgeschlossenes Projekt

EK-Unterschriftsdatum 29 November 2017

Startdatum 1 Oktober 2017

Enddatum 30 September 2019

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 3 957 000,00

EU-Beitrag € 3 957 000,00

Koordiniert durch

TC BIOPHARM LIMITED
United Kingdom

Ziel

Europe is experiencing an unprecedented cancer epidemic, driven by our ageing population. Traditional cancer treatments such as surgery, chemotherapy and radiation therapy have demonstrated very limited efficacy for patients with late-stage disease and often cause considerable side effects.
Cell therapies are the next breakthrough in oncology, but autologous cells must be harvested from each patient, expanded for several weeks in vitro and re-administered to the same patient while hospitalized.
TCB, a Scottish SME, brings the first allogeneic gamma delta T cell therapy (OmnImmune) where T cells harvested from healthy donors are used to treat multiple recipients.
OmnImmune represents a truly disruptive, step-changing approach to the treatment of a wide variety of cancers. It has the potential to be manufactured for large market segments at a lower cost than competitors and provide valuable increases to the quality of life of life.
OmnImmune will provide next generation cancer treatment at 20% of the cost of any other cell therapy, saving €24Bn per year for 60,000 patients treated.
OmnImmune’s unique characteristics make it a truly disruptive treatment solution for patients and clinicians:
Multifunctional treatment solution: available to all cancer patients, regardless of their disease grade or immune status
Predicted high safety profile: minimal side-effects based on clinical data from trials of autologous GDT cells (to be confirmed in dose-escalation clinical trial)
Ease of use and lower cost: frozen dose-ready units available for immediate patient administration.
The SME Instrument funding will accelerate the development of the OmnImmune therapy and reduce its time to market from 10 years to 6 years. This will allow OmnImmune to reach the market by 2024.

Wissenschaftliches Gebiet

• Medizin- und Gesundheitswissenschaften › Klinische Medizin › Chirurgie
• Medizin- und Gesundheitswissenschaften › Grundlagenmedizin › Pharmakologie und Pharmazie › Arzneimittel
• Medizin- und Gesundheitswissenschaften › Medizinische Biotechnologie › Zelltechnik › Stammzelle
• Medizin- und Gesundheitswissenschaften › Klinische Medizin › Hämatologie
• Medizin- und Gesundheitswissenschaften › Klinische Medizin › Onkologie › Leukämie

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

TC BIOPHARM LIMITED

• Netto-EU-Beitrag: € 3 957 000,00
• Adresse: Maxim 1 parklands way 2 holytown motherwell lanarkshire ; ML14WQ Holytown ; Vereinigtes Königreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Scotland › West Central Scotland › North Lanarkshire
• Region: Scotland › West Central Scotland › North Lanarkshire
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Weitere Finanzmittel: € 0,00